CX3CR1 Antibody, anti-human, REAfinity™
Synonyms: CCRL1, CMKBRL1, CMKDR1, GPR13, GPRV28, V28, GPRV28, RBS11
RECOMBINANT EXTENDED VALIDATION
Bioz Star94/100 Bioz rating
15 Citations
Clone:
REA385 | K0124E1
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, MC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CX3CR1 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
PE
Vio Bright V423
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-119-579, 130-119-678
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-CX3CR1 antibodies or with the corresponding REA Control (S) antibodies (left images) as well as with CD3 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
frozen – PFA
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC, ICC
Conjugate:
APC
Used products:
130-119-579, 130-119-678
Testing grade:
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-119-579, 130-119-678
Testing grade:
Mass cytometry applications
pure
Conjugate:
pure
Used products:
130-122-286
Extended validation for CX3CR1 Antibody, anti-human, REAfinity™
Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CX3CR1. Human peripheral blood mononuclear cells (PBMCs) were stained with CX3CR1 antibodies and with a suitable counterstaining. As a control, CX3CR1 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Extended-Validation detailed information image
Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CX3CR1 (REA385). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CX3CR1 Antibody, anti-human, REAfinity™
Overview

Clone REA385 recognizes the human CX3C chemokine receptor 1 antigen, a 40 kDa G-protein–coupled multi-pass membrane protein also known as fractalkine receptor. CX3CR1 is expressed on natural killer (NK) cells, T cell subsets, monocytes/macrophages, dendritic cells (DCs), and some malignant epithelial cells. Binding of CX3CR1 to the membrane-bound form of the chemokine CX3CL1 promotes cell-cell adhesion, whereas the soluble form induces cell migration of CX3CR1-bearing cells such as monocytes, NK cells, T cells, DCs, and macrophages including microglia. CX3CR1 plays also an important role in the formation of transepithelial dendrites by intestinal DCs. Failure in the CX3CL1/CX3CR1 interaction may contribute to the development of several inflammatory diseases including atherosclerosis, psoriasis, rheumatoid arthritis, and experimental autoimmune myositis.

Additional information: Clone REA385 displays negligible binding to Fc receptors.

Alternative names

CCRL1, CMKBRL1, CMKDR1, GPR13, GPRV28, V28, GPRV28, RBS11

Detailed product information

Technical specifications

Clone
REA385
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, non-human primate
Cross-reactivity
rhesus monkey (Macaca mulatta), cynomolgus monkey (Macaca fascicularis)
Antigen
CX3CR1
Molecular mass of antigen [kDa]
40
Distribution of antigen
NK cells, T cells, dendritic cells, macrophages, monocytes, epithelial cells
Entrez Gene ID
RRID
AB_2928610, AB_2801867, AB_2751738, AB_2928611, AB_2751798, AB_2801963, AB_2801984

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CX3CR1 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?